期刊文献+

奥曲肽对人肝癌细胞Huh-7增殖、细胞周期和凋亡的影响 被引量:4

Effects of octreotide on proliferation,cell cycle and apoptosis in human liver cancer Huh-7 cells
原文传递
导出
摘要 目的探讨奥曲肽对人肝癌细胞Huh-7增殖、细胞周期及凋亡的影响。方法 Huh-7细胞用不同浓度奥曲肽(0、10-9、10-8、10-7、10-6、10-5 mol/L,分别为A、B、C、D、E、F组)处理,MTT法检测细胞生长抑制率,流式细胞术检测细胞周期和凋亡,Western blot法检测半胱天冬氨酸蛋白酶3(Caspase-3)表达。结果与A组相比,其余各组Huh-7细胞的生长抑制率、G1期细胞的比例、凋亡率及Caspase-3蛋白表达均以浓度依赖性的方式明显增加。结论奥曲肽可显著抑制Huh-7细胞的生长,诱导细胞周期阻滞和细胞凋亡;且奥曲肽可能通过启动Caspases途径诱导人肝癌细胞Huh-7凋亡。 Objective To investigate the effects of octreotide on the proliferation,cell cycle and apoptosis in human liver cancer Huh-7 cells.Methods After treated with different concentrations of octreotide(0,10-9,10-8,10-7,10-6 and 10-5 mol/L,named groups of A,B,C,D,E and F,respectively),the inhibition rate of cell growth was measured by MTT assay,the cell cycle and apoptosis were detected by flow cytometry,and the protein expression of cystein asparate proteinase-3(Caspase-3) was analyzed by Western blot.Results Compared with group A,the inhibition rate of cell growth,proportion of G1 phase cells,apoptosis rate and protein expression of Caspase-3 were all significantly increased in a concentration-dependent manner in the other groups.Conclusion Octreotide can significantly inhibit the growth of Huh-7 cells,induce cell cycle arrest and cell apoptosis,which is probably via Caspases pathway.
出处 《江苏医药》 CAS CSCD 北大核心 2012年第5期497-499,F0002,共4页 Jiangsu Medical Journal
基金 江苏省重点医学基金(135-10)
关键词 奥曲肽 肝癌 细胞周期 凋亡 半胱天冬氨酸蛋白酶3 Octreotide Liver cancer Cell cycle Cell apoptosis Cystein asparate proteinase-3
  • 相关文献

参考文献1

二级参考文献1

共引文献22

同被引文献65

  • 1许秋然,郑鑫,姚英民,杨威,刘青光.肝移植术与肝切除术治疗原发性肝癌的meta分析[J].西安交通大学学报(医学版),2012,33(5):576-582. 被引量:7
  • 2陈仲庚.艾森克人格问卷的项目分析[J].心理学报,1983,15(2):211-218. 被引量:381
  • 3Saif MW. Advancements in the management of pancreatic cancer [ J]. J Pancreas,2013,14(2) :112 -118. 被引量:1
  • 4Stomiolo AM, Enas NH, Brown CA, et al. An investigational new drug treatment program for patients with gemcitabine:resuhs for o- ver 3000 patients with panereatic carcinoma [ J]. Cancer, 1999,85 (6) :1261 - 1268. 被引量:1
  • 5Ioka T, Katayama K, Tanaka S, et al. Safety and effectiveness of gemcitabine in 855 patients with pancreatic cancer under Japanese clinical practice based on post - marketing surveillance in Japan [J]. Jpn J Clin 0ncol,2013,43(2) :139 - 145. 被引量:1
  • 6Giuliani F, Di Maio M, Colucei G, et al. Conventional chemotherapy of advanced pancreatic cancer [ J]. Curr Drug Targets,2012, 13 (6) :795 -801. 被引量:1
  • 7Colucci G, Labianca R, Di Costanzo F. Randomized phase III trial of gemcitabine plus cisplatin compared with single - agent gemcit- abine as first - line treatment of patients with advanced pancreatic cancer:the GIP-1 study[J]. J Clin Oncol,2010,28(10) :1645 - 1651. 被引量:1
  • 8Ciliberto D, Botta C, Correale P, et al. Role of gemcitabine - based combination therapy in the management of advanced pancreatic cancer: a meta - analysis of randomised trials [ J ]. Eur J Cancer, 2013,49(3) :593 -603. 被引量:1
  • 9Hidalgo M. Pancreatic cancer [ J ]. N Engl J Med,2010,362 ( 17 ) : 1605 - 1617. 被引量:1
  • 10Chan MM, Mengshol JA. Octreotide:a drug often used in the criti- cal care setting but not well understood [ J ]. Chest,2013,144 (6) : 1937 - 1945. 被引量:1

引证文献4

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部